Application of an Aptamer-Based Proteomics Assay (SOMAscan™) in Rat Cerebrospinal Fluid

  • Alba Simats
  • Laura Ramiro
  • Joan Montaner
  • Teresa García-Berrocoso
Part of the Methods in Molecular Biology book series (MIMB, volume 2044)


The exploration of the cerebrospinal fluid (CSF) through proteomics techniques might help in the search of molecular biomarkers relevant to neurological pathologies. Aiming this, we describe here a commercially available multiplexed proteomics technology based on the use of modified aptamers (SOMAscan™ assay). From our experience in exploring the rat CSF proteome, we detail the basic principles of this oligonucleotide-based proteomics approach, as well as the main data-processing steps to obtain relative quantitative values for proteins that could discriminate among different brain conditions, as an attempt in the search of neurological biomarkers. Finally, we give some tips on performing the SOMAscan assay and key recommendations on the verification analyses of the resulting candidate biomarkers.

Key words

Aptamer CSF Multiplex Proteome Rat SOMAscan™ 



This work was supported by a PI15/00354 grant from Fondo de Investigaciones Sanitarias of Instituto de Salud Carlos III (co-financed by the European Regional Development Fund, FEDER). Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ (RD16/0019). L. R is supported by a pre-doctoral fellowship from the Instituto de Salud Carlos III (IFI17/00012).


  1. 1.
    Brinker T, Stopa E, Morrison J, Klinge P (2014) A new look at cerebrospinal fluid circulation. Fluids Barriers CNS 11:10CrossRefGoogle Scholar
  2. 2.
    Tu C, Rudnick PA, Martinez MY et al (2010) Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res 9:4982–4991CrossRefGoogle Scholar
  3. 3.
    Gold L, Ayers D, Bertino J et al (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5:e15004CrossRefGoogle Scholar
  4. 4.
    Röthlisberger P, Gasse C, Hollenstein M (2017) Nucleic acid aptamers: emerging applications in medical imaging, nanotechnology, neurosciences, and drug delivery. Int J Mol Sci 18:2430CrossRefGoogle Scholar
  5. 5.
    Gold L, Walker JJ, Wilcox SK, Williams S (2012) Advances in human proteomics at high scale with the SOMAscan proteomics platform. N Biotechnol 29:543–549CrossRefGoogle Scholar
  6. 6.
    Simats A, García-Berrocoso T, Ramiro L et al (2018) Characterization of the rat cerebrospinal fluid proteome following acute cerebral ischemia using an aptamer-based proteomic technology. Sci Rep 8:7899CrossRefGoogle Scholar
  7. 7.
    Kraemer S, Vaught JD, Bock C et al (2011) From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay. PLoS One 6:e26332CrossRefGoogle Scholar
  8. 8.
    Keeney TR, Bock C, Gold L et al (2009) Automation of the SomaLogic proteomics assay: a platform for biomarker discovery. J Lab Autom 14:360–366CrossRefGoogle Scholar
  9. 9.
    Mahat MYA, Fakrudeen Ali Ahamed N, Chandrasekaran S et al (2012) An improved method of transcutaneous cisterna magna puncture for cerebrospinal fluid sampling in rats. J Neurosci Methods 211:272–279CrossRefGoogle Scholar
  10. 10.
    Rohloff JC, Gelinas AD, Jarvis TC et al (2014) Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents. Mol Ther Nucl Acids 3:e201CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Alba Simats
    • 1
  • Laura Ramiro
    • 1
  • Joan Montaner
    • 1
  • Teresa García-Berrocoso
    • 1
  1. 1.Neurovascular Research Laboratory, Vall d’Hebron Institute of Research (VHIR)Universitat Autònoma de BarcelonaBarcelonaSpain

Personalised recommendations